Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: Clinical implications

Clinical Infectious Diseases

Volumn 50, Issue 9, 2010, Pages 1300-1308

  Negredo, Eugènia ^a   Massanella, Marta ^a   Puig, Jordi ^a   Pérez Álvarez, Núria ^a,b   Gallego Escuredo, José Miguel ^c,d   Villarroya, Joan ^c,d   Villarroya, Francesc ^c,d   Moltó, José ^a   Santos, José Ramón ^a   Clotet, Bonaventura ^a   Blanco, Julià ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CASPASE 3; CD4 ANTIGEN; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL DEATH; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TREATMENT RESPONSE; VIROLOGY; VIROTHERAPY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOPTOSIS; CASE-CONTROL STUDIES; CASPASE 3; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; UNITED STATES; VIRAL LOAD;

EID: 77950979658     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651689     Document Type: Article

References (36)

1. 1. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/ μL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005;41:361-372. (Pubitemid 41022115)
2. Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JS. Diseaseprogression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 2006;20:371-377.
3. Baker JV, Peng G, Rapkin J, et al. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr 2008; 48:541-546.
4. Moore RD, Gebo KA, Lucas GM, Keruly JC. Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis 2008; 47:1102-1104.
5. Gazzola L, Tincati C, Bellistri GM, Monforte A, Marchetti G. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009; 48:328-337.
6. 6. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologie responses to a protease inhibitor-containing regimen. J Infect Dis 2001;183: 1328-1335. (Pubitemid 32337114)
7. 7. Tan R, Westfall AO, Willig JH, et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologie responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008;47:553-558. (Pubitemid 351442024)
8. Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009;48:787-794.
9. 9. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998; 12:745-750. (Pubitemid 28190697)
10. 10. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002; 16:359-367. (Pubitemid 34165367)
11. 11. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183:1290-1294. (Pubitemid 32281572)
12. 12. Egger M, May M, Chene G, et al. Prognosis of'HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-129. (Pubitemid 34786200)
13. Korner C, Kramer B, Schulte D, et al. Effects of HCV coinfection on apoptosis of CD4+ T cells in HIV-positive patients. Clin Sci (Lond) 2009;116:861-870.
14. 14. Nunez M, Soriano V, Lopez M, et al. Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients. Clin Infect Dis 2006;43:1209-1212. (Pubitemid 44632808)
15. Peters L, Mocroft A, Soriano V, et al. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologie suppression. J Acquir Immune Defic Syndr 2009;50:457-463.
16. 16. Teixeira L, Valdez H, McCune JM, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001;15:1749-1756. (Pubitemid 32939234)
17. 17. Benveniste O, Flahault A, Rollot F, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005; 191:1670-1679. (Pubitemid 40656755)
18. 18. Marchetti G, Gori A, Casabianca A, et al. Comparative analysis of T cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006; 20:1727-1736. (Pubitemid 44299364)
19. 19. Kitchen CM, Philpott S, Burger H, Weiser B, Anastos K, Suchard MA. Evolution of human immunodeficiency virus type 1 coreceptor usage during antiretroviral therapy: a Bayesian approach. J Virol 2004; 78:11296-11302. (Pubitemid 39299669)
20. Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4+ T cell reconstitution in HIVinfected patients on long-term highly active antiretroviral therapy. AIDS 2008; 22: 2035-2038.
21. 21. Negredo E, Molto J, Burger D, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofbvir-based regimens despite undetectable viral load. AIDS 2004; 18:459-463. (Pubitemid 38365873)
22. 22. Gougeon ML, Lecoeur H, Dulioust A, et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 1996; 156: 3509-3520. (Pubitemid 26123568)
23. 23. Blanco J, Barretina J, Clotet B, Este JA. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. J Leukoc Biol 2004; 76: 804-811. (Pubitemid 39313716)
24. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
25. Badley AD, Pilon AA, Landay A, Lynch DH. Mechanisms of HIVassociated lymphocyte apoptosis. Blood 2000; 96: 2951-2964.
26. Laurent-Crawford AG, Krust B, Muller S, et al. The cytopathic effect of HIV is associated with apoptosis. Virology 1991; 185:829-839.
27. Terai C, Kornbluth RS, Pauza CD, Richman DD, Carson DA. Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest 1991; 87: 1710-1715.
28. 28. Arnoult D, Petit F, Lelievre JD, et al. Caspase-dependent and -independent T cell death pathways in pathogenic simian immunodeficiency virus infection: relationship to disease progression. Cell Death Differ 2003; 10: 1240-1252. (Pubitemid 37407126)
29. Weaver JG, Tarze A, Moffat TC, et al. Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor. J Clin Invest 2005; 115: 1828-1838.
30. Hisatomi T, Nakazawa T, Noda K, et al. HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice. J Clin Invest 2008;118: 2025-2038.
31. Sloand EM, Kumar PN, Kim S, Chaudhuri A, Weichold FF, Young NS. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999; 94: 1021-1027.
32. Badley AD. In vitro and in vivo effects of HIV protease inhibitors on apoptosis. Cell Death Differ 2005; 12(suppl 1):924-931.
33. Estaquier J, Lelievre JD, Petit F, et al. Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T cell death. J Virol 2002; 76: 5966-5973.
34. Meroni L, Varchetta S, Manganaro D, et al. Reduced levels of CD4 cell spontaneous apoptosis in human immunodeficiency virus-infected patients with discordant response to protease inhibitors. J Infect Dis 2002; 186:143-144.
35. Benito JM, Lopez M, Martin JC, et al. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse-transcriptase inhibitors. AIDS Res Hum Retroviruses 2002; 18:1379-1388.
36. Landay AL, Spritzler J, Kessler H, et al. Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen. J Infect Dis 2003; 188: 1444-1454.